|
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
2, BUTABARBITAL SODIUM SARISOL, BUTABARBITAL SODIUM APPENDIX A PRODUCT NAME INDEX SATRIC, METRONIDAZOLE SCABENE, LINDANE SCANDONEST L, LEVONORDEFRIN SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE SCLEROSOL, TALC SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE SEASONALE, ETHINYL ESTRADIOL SECOBARBITAL SODIUM, SECOBARBITAL SODIUM SECONAL SODIUM, SECOBARBITAL SODIUM SECREFLO, SECRETIN...
|
|
|
C:\LORI\ALCON\50616 S016 017 019 cmc & label AP ltr 3-18-03.doc
Page 3 NDA 50- 616/ S- 016, S- 017 & S- 019 TobraDex ® (tobramycin and dexamethasone ophthalmic ointment) Sterile DESCRIPTION: TOBRADEX ® (tobramycin and dexamethasone ophthalmic ointment) is a sterile, multiple dose antibiotic and steroid combination for topical ophthalmic use
The chemical structures for tobramycin and dexamethasone are...
author: Lori Gorski
|
|
|
C:\LORI\ALCON\50616 S016 017 019 cmc & label AP ltr 3-18-03.doc page 1
author: Lori Gorski
|
|
|
4:00 page 23
author: Christine Wildman
|
|
|
FDA Drug Approvals List- April 1999
Original Application #: 050760 Approval Date: 15-APR-99 Trade Name: AMOXIL Chemical Type: 3 Therapeutic Potential: S Dosage Form: SUSPENSION Applicant: SMITHKLINE BEECHAM PHARMACEUTICALS Active Ingredient(s): AMOXICILLIN OTC/RX Status: RX Indication(s):For the use of Amoxil for oral suspension 200mg/5mL and 400mg/5mL in divided doses q12h Original Application #: 020924 Approval Date:...
|
|
|
http://www.fda.gov/cder/ogd/rld/50616s11.pdf page 3
|
|
|
OP2 outline v2
INNOVATIONS IN OPHTHALMIC PHARMACEUTICALS, 1996Ð 2005 Chapter 1: Executive Summary Research and Development Environment Demographics Major Markets Chapter 2: Introduction Study Objectives Scope and Organization Part I: Environment Part II: Disease and Products Overview Part III: Strategic ...
author: Dan
|
|
|
Drug Approvals September 1996
CATARRHALIS TO THE INDICATIONS AND USAGE SECTION Approvable Original New Drug Applications Original Application #: 020535 Approvable Date: 30-SEP-96 Trade Name: DURACT Dosage Form: CAPSULE Applicant: WYETH AYERST LABORATORIES INC Active Ingredient(s): BROMFENAC SODIUM OTC/RX Status: RX Original Application #: 020690 Approvable Date: 19-SEP-96 Trade Name: ARICEPT Dosage Form: TABLET...
|
|
|
1998 Warning Letters and Untitled Letters to Pharmaceutical Companies
Food and Drug Administration • Center for Drug Evaluation and Research Compliance Activities Search Warning Letters and Untitled Letters to Pharmaceutical Companies 1998 These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office
DDMAC 4/27 5/7 MUSE (alprostadil) urethral suppository Vivus DDMAC 4/1 4/9 Nicotrol Inhaler (nicotine)...
|
|
|
1999 Warning Letters and Untitled Letters to Pharmaceutical Companies
DSI 4/9/99 5/21/99 Combivir Tablets Glaxo Wellcome DDMAC 4/23/99 5/18/99 Detrol (tolterodine tartrate) tablets Pharmacia & Upjohn DDMAC 4/13/99 5/18/99 Ditropan XL (oxybutynin chloride) tablets Alza Corporation DDMAC 4/2/99 4/14/99 Livostin (levocabastine HCl) ophthalmic suspension Ciba Vision DDMAC 4/6/99 4/14/99 Lovenox (enoxaparin sodium) injection Rhone-Poulenc Rorer DDMAC 4/8/99...
|
|
|
Microsoft Word - Medication_Listing.doc page 22
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc page 51
author: Wendy Daws
duplicates:
http://www.crha-health.ab.ca/clin/cme/ccmed/ccform/mindext.pdf
|
|
|
Microsoft Word - Master_Index.doc
Continuing Care Pharmacy & Therapeutics Formulary ML- Index SECTION SUBJECT Page 50 of 58 MASTER INDEX Medication Listing Index YY MM DD Original 00 10 30 Revised 01 12 19 Revised 03 10 23 DRUG NAME PAGE CLASS tacrolimus (Prograf®) Refer To Province Wide Services (PWS- 01) 38 92: 00 Tambocor® Restricted Status (RS- 28) 9 24: 04 tamsulosin hydrochloride (Flomax®)...
author: Wendy Daws
|
|
|
C:\LORI\ALCON\50592 slr32 AP ltr 6-20-03.doc page 1
author: Lori Gorski
|
|
|
C:\LORI\ALCON\50616 S016 017 019 cmc & label AP ltr 3-18-03.doc page 1
author: Lori Gorski
|
|
|
C:\LORI\ALCON\50616 S016 017 019 cmc & label AP ltr 3-18-03.doc page 4
author: Lori Gorski
|
|
|
C:\LORI\ALCON\50616 S016 017 019 cmc & label AP ltr 3-18-03.doc page 3
author: Lori Gorski
|
|
|
C:\LORI\ALCON\50616 S016 017 019 cmc & label AP ltr 3-18-03.doc page 2
author: Lori Gorski
|
|
|
4:00 page 44
author: Christine Wildman
|
|
|
Medicines, Ethics and Practice page 8
|
|
|
P970024/S43 page 38
author: Author: ODE
subject: Issued: 06-13-2002
|
|
|
http://www.fda.gov/cder/ogd/rld/50616s11.pdf page 4
|
|
|
http://www.fda.gov/cder/ogd/rld/50616s11.pdf page 1
|
|
|
OP2 outline v2 page 2
HG Pars (Cannabis) Glycomed (Galardin) Peptide Technology (CBT- 101) Glaucoma Market Forecast Market Overview Major Determinants of Market Growth Demographics New Product Entry Total Market Forecast Chapter 5: Cataracts Disease Background Barriers to Drug Development Types of Cataracts ...
author: Dan
|
|
|
A to Z List - Medication Information
A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z - A Abacavir Abacavir, lamivudine, zidovudine Acyclovir Alendronate Allopurinol Amifostine Amitriptyline Amlodipine Amoxicillin Amoxicillin / clavulanic acid Amphotericin B Ampicillin Amprenavir Anti-thymocyte globulin Asparaginase Atenolol Atovaquone Atracurium Azithromycin top - -...
author: St. Jude Children's Research Hospital
|
